A Phase 2 interventional study of Tolterodine & Pregabalin and Tolterodine in Overactive Bladder, sponsored by Pfizer. Completed at 23 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-12-21.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing tolterodine in Urinary Bladder, Overactive — 3 open to participants now, 3 under way, 1 of them phase 3. tolterodine · Urinary Bladder, Overactive.
Among the 30 studies testing tolterodine in Urinary Bladder, Overactive, this one is the 10th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2005, is one of 3 in phase 2, and was the 12th registered.
860 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.
Browse Urinary Bladder, Overactive studies →3 of the 30 studies testing tolterodine in Urinary Bladder, Overactive are open now, in 2 countries. Recruiting first, the newest first:
Far Eastern Memorial Hospital · Sites in Taiwan
Ages 20+ · Women only
University of California, San Francisco · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Far Eastern Memorial Hospital · Sites in Taiwan
Ages 18+ · Women only
By country, each count listing its studies:
tolterodine: first FDA approval 1998 (DETROL). What it is approved for, and how studies give it, is on its page →
Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 4 · Phase 3 4 · Phase 4 15
First in 2003; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 188 is above the median of 70 across 651 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 100 across the 29 interventional studies. Of the 24 that completed or were terminated, 8 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 30 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
35 studies in Urinary Bladder, Overactive by Pfizer: none open now, none under way, none of them phase 3. Of 35 finished, 22 (63%) have results posted.
Among the 35 studies in Urinary Bladder, Overactive by Pfizer, this one is the 14th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2005, is one of 5 in phase 2, and was the 14th registered.
Pfizer’s Urinary Bladder, Overactive studies by the year they started, since 2003.
1 of the studies testing tolterodine in Urinary Bladder, Overactive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05362292University of California, San FranciscoTReating Incontinence for Underlying Mental and Physical Health | 2027-05-02 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing tolterodine in Urinary Bladder, Overactive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 35 in Urinary Bladder, Overactive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Tolterodine is approved for use in the treatment of overactive bladder (OAB). The study is designed to a investigate whether pregabalin may have efficacy in OAB and whether the efficacy is altered when it is combined with tolterodine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Tolterodine SR 2 mg once daily combined with pregabalin 75 mg twice daily
Drug: Tolterodine & Pregabalin
Tolterodine SR 4 mg once daily
Drug: Tolterodine
Placebo
Drug: Placebo
Tolterodine SR 4 mg once daily combined with pregabalin 150 mg twice daily
Drug: Tolterodine & Pregabalin
Pregabalin 150 mg twice daily
Drug: Pregabalin
Drug pages: Tolterodine · Pregabalin
Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
Placebo, Oral, twice daily for 4 weeks
Drug pages: Tolterodine · Pregabalin
Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
Pregabalin, Oral, 150 mg twice daily for 4 weeks
Change in mean voided volume per micturition (from baseline).
Time frame: 4 weeks
Percentage and absolute change in incontinence episode frequency after 4 weeks of treatment (for subjects with incontinence at baseline).
Time frame: 4 Weeks
Percentage and absolute change in urgency episode frequency
Time frame: 4 Weeks
Mean severity of urgency episodes
Time frame: 4 Weeks
Percentage and absolute change in micturition frequency
Time frame: 4 Weeks
Percentage and absolute change in normalized micturition frequency (NMF)
Time frame: 4 Weeks
Patient perception of their urinary urgency (using the OAB-q symptom severity scale)
Time frame: 4 Weeks
Patient perception of Health Related Quality of Life (using the OAB-q SF HRQL scale)
Time frame: 4 Weeks
Patient Perception of Bladder Condition (PPBC) scale
Time frame: 4 Weeks
The record gives a start of Dec 2005 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tolterodine · Pregabalin